King's College London

Research portal

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Research output: Contribution to journalArticlepeer-review

Bryan Krastins, Amol Prakash, David A. Sarracino, Dobrin Nedelkov, Eric E. Niederkofler, Urban A. Kiernan, Randall Nelson, Maryann S. Vogelsang, Gouri Vadali, Alejandra Garces, Jennifer N. Sutton, Scott Peterman, Gregory Byram, Bruno Darbouret, Joelle R. Perusse, Nabil G. Seidah, Benoit Coulombe, Johan Gobom, Erik Portelius, Josef Pannee & 5 more Kaj Blennow, Vathany Kulasingam, Lewis Couchman, Caje Moniz, Mary F. Lopez

Original languageEnglish
Pages (from-to)399-410
Number of pages12
JournalClinical Biochemistry
Issue number6
PublishedApr 2013

King's Authors


Objectives: The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum.

Design and methods: The described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and accurate quantification of targeted peptides, including clinically relevant sequence or truncated variants.

Results: In this report, we demonstrate the rapid development of MSIA-SRM assays for sixteen different target proteins spanning seven different clinically important areas (including neurological, Alzheimer's, cardiovascular, endocrine function, cancer and other diseases) and ranging in concentration from pg/mL to mg/mL. The reported MSIA-SRM assays demonstrated high sensitivity (within published clinical ranges), precision, robustness and high-throughput as well as specific detection of clinically relevant isoforms for many of the target proteins. Most of the assays were tested with bona-fide clinical samples.

In addition, positive correlations, (R2 0.67-0.87, depending on the target peptide), were demonstrated for MSIA-SRM assay data with clinical analyzer measurements of parathyroid hormone (PTH) and insulin growth factor 1 (IGF1) in clinical sample cohorts.

Conclusions: We have presented a practical and scalable method for rapid development and deployment of MS-based SRM assays for clinically relevant proteins and measured levels of the target analytes in bona fide clinical samples. The method permits the specific quantification of individual protein isoforms and addresses the difficult problem of protein heterogeneity in clinical proteomics applications.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454